Amarin Corporation plc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AMRN Nasdaq 2836 www.amarincorp.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Amarin Corporation plc

Amarin Receives National Reimbursement for VAZKEPA® in Italy - Dec 16th, 2024 12:00 pm
Amarin Appoints Peter Fishman Chief Financial Officer - Dec 13th, 2024 2:00 pm
After Plunging -19.13% in 4 Weeks, Here's Why the Trend Might Reverse for Amarin (AMRN) - Nov 19th, 2024 2:35 pm
Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual Scientific Sessions - Nov 11th, 2024 1:00 pm
Amarin Corp PLC (AMRN) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines Amid ... - Nov 1st, 2024 7:19 am
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates - Oct 31st, 2024 1:32 pm
Amarin Plc (AMRN) Q3 2024 Earnings Call Transcript - Oct 31st, 2024 6:00 am
Amarin: Q3 Earnings Snapshot - Oct 30th, 2024 9:21 pm
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update - Oct 30th, 2024 8:05 pm
Amarin Corp PLC (AMRN) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges and ... - Oct 9th, 2024 7:32 pm
Amarin Announces Two Upcoming Investor Events - Oct 1st, 2024 12:00 pm
Here's Why We're Not At All Concerned With Amarin's (NASDAQ:AMRN) Cash Burn Situation - Sep 18th, 2024 11:06 am
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting - Sep 9th, 2024 11:30 am
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress - Aug 22nd, 2024 12:30 pm
Exploring 3 Undervalued Small Caps In United States With Insider Action - Aug 8th, 2024 11:01 am
Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat - Aug 1st, 2024 4:59 pm
Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript - Jul 31st, 2024 6:15 pm
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update - Jul 31st, 2024 11:00 am
3 Breakthrough Stocks Under $10 Set for Massive Upside - Jul 29th, 2024 6:26 pm
Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar? - Jul 23rd, 2024 10:13 am